Send yourself the details of this trial and next steps
Please provide a valid email address.
Send yourself the details of this trial and next steps
Please provide a valid email address.
This doesn't look like a valid phone number. Please check.
Both First Name and Last Name are required. Please check.
Home»Hodgkin's lymphoma» Looking for Hodgkin lymphoma patients to test the safety and effectiveness of the combined treatment Ibrutinib and Brentuximab Vedotin
Clinical Trial
Looking for Hodgkin lymphoma patients to test the safety and effectiveness of the combined treatment Ibrutinib and Brentuximab Vedotin
This phase 2 trial aims to test the safety and effectiveness of a combined treatment with ibrutinib (Imbruvica) and brentuximab vedotin (Adcetris) in recurrent (when the cancer comes back) Hodgkin lymphoma patients or in those who did not respond to the first line of treatment. This trial is recruiting in California, United States.
The details
Ibrutinib is a treatment that stops tumor growth by blocking the division and growth of cancer cells. Immunotherapies such as brentuximabvedotin bind to proteins on the cancer cell, leading to cell death. The combination of these two agents may increase the effectiveness of the treatment.
The current trial will examine this combined treatment followed recurrence or failure of the firstline treatment. The main outcomes to be measured will include the tumor response to the treatment, overall survival and treatment toxicity.
Who are they looking for?
This trial will recruit 39 participants with recurrent Hodgkin lymphoma or those who did not respond to the first line of treatment. Participants must have normal blood values and be over 40 kg. Patients must not have an allergy to brentuximabvedotin, must not have had a recent infection, and must not have any known bleeding disorders. Participants must not have peripheral neuropathy (damage of nerves), must not have a history of stroke and must not being treated with anti-coagulants. Patients must not have active hepatitis B or C.
How will it work
Patients will receive ibrutinib orally, once a day on days 1-21 and injections of brentuximab vedotin over 30 minutes on day 1. Treatment repeats every 21 days until cancer progression or toxicity. After the treatment, patients will be followed up every 3 months for up to 2 years.
The tumor response rate will be determined following the last treatment and side effects will be reported.
